Naltrexone/Bupropion
ApprovedSmall molecule
Novo NordiskNaltrexone/Bupropion is one of 76 small molecule programs targeting Breast Cancer. It is currently in Approved.
3
Indications
8
Total Trials
2
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Naltrexone/Bupropion
Novo NordiskApproved
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
DATROWAY
Daiichi SankyoPreclinical
Adenocard
AstellasPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Spravato
WWim Janssens
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity4 trials
Anti-obesity Pharmacotherapy and Inflammation
Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled
Breast Cancer1 trial
Metformin1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Naltrexone/Bupropion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company